Drug delivery systems market seen reaching $62.89 billion by 2030

The global drug delivery systems market is projected to grow from $47.54 billion in 2026 to $62.89 billion by 2030, driven by biologics, personalized medicine and new delivery technologies. North America leads now, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Drug delivery systems are becoming more important as drug makers look for ways to improve dosing, reduce side effects and support patient adherence. - The market outlook points to steady demand across chronic disease treatment, biologics and self-administration devices. - Growth in respiratory disease cases adds pressure for more targeted delivery methods, especially for lung-focused therapies.

What happened: - The Business Research Company projected the drug delivery systems market will rise from $44.21 billion in 2025 to $47.54 billion in 2026. - The forecast implies 7.5% growth in 2026. - The market is expected to reach $62.89 billion by 2030. - The longer-term forecast calls for a 7.2% compound annual growth rate through 2030. - The company published the outlook on Aug. 5, 2026. - A free sample report and the full market report are available online.

The details: - Drug delivery systems are technologies designed to transport medications safely within the body. - These systems control the timing, dose and location of drug release. - The goal is to maximize therapeutic effect while minimizing adverse effects. - The market’s recent growth has been supported by continued use of oral and injectable delivery methods. - Other drivers include a limited range of biologics formulations, expanding hospital and clinical infrastructure, rising chronic disease burden and higher pharmaceutical R&D spending. - Future growth is expected to come from advances in polymer-based and lipid-based delivery technologies. - Personalized medicine is expected to increase demand for more precise delivery options. - Inhalation and transmucosal delivery routes are gaining use. - Homecare and self-administration devices are seeing greater adoption. - Digital monitoring and smart drug delivery systems are emerging as a major trend. - Targeted and controlled release platforms are getting more attention. - Biologics and advanced therapeutics are expanding the market’s addressable use cases. - Minimally invasive and needle-free solutions are being developed to improve patient safety and adherence. - Rising respiratory disease prevalence is a major growth factor. - Conditions including asthma, chronic obstructive pulmonary disease, pulmonary fibrosis and cystic fibrosis are becoming more common. - Air pollution is contributing to worsening lung health and higher disease rates. - Drug delivery technologies can deliver medicines directly to the lungs and reduce systemic side effects. - In March 2025, the UK Health Security Agency reported a 13% increase in tuberculosis cases in England in 2024, to 5,480 from 4,850 the year before. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing regional market in the coming years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a shift away from one-size-fits-all drug delivery toward systems that support precise, patient-specific treatment. - Growth in homecare and self-administration suggests more care may move outside hospitals. - The emphasis on smart, needle-free and controlled-release platforms signals that patient convenience is becoming a bigger commercial advantage.

What's next: - Market growth will likely depend on how quickly drug makers and device developers scale advanced delivery technologies. - Wider adoption of biologics, personalized medicine and digital monitoring could reshape product development priorities through 2030. - Regional gains in Asia-Pacific may accelerate as healthcare spending and awareness rise.